Santersus Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Reverse Merger
- (Announced)
- Investors
-
2
Santersus General Information
Description
Developer of a therapeutic apheresis technology designed to control human immune and inflammatory responses to disease. The company's technology focuses on the extracorporeal removal of cell-free DNA and neutrophil extracellular traps from patient plasma, enabling healthcare providers to treat severe inflammatory conditions and improve patient outcomes in critical care.
Contact Information
Website
www.santersus.comCorporate Office
- Care of Lex Futura AG Nüschelerstrasse 45
- 8001 Zürich
- Switzerland
Corporate Office
- Care of Lex Futura AG Nüschelerstrasse 45
- 8001 Zürich
- Switzerland
Santersus Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Reverse Merger | 16-Sep-2026 | Announced | Clinical Trials - General | |||
| 4. Later Stage VC (Series A) | 25-Apr-2025 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC | 01-Jul-2021 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 01-Sep-2020 | $1.11M | $1.93M | Completed | Clinical Trials - General | |
| 1. Capitalization | 01-Sep-2020 | $824K | $824K | Completed | Clinical Trials - General |
Santersus Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 192,306 | $0.117130 | $4.57 | $4.57 | 1x | $4.57 | 8.88% | |
| Ordinary | 62,768 | $0.117130 | $4.83 | $4.83 | 1x | $4.83 | 2.9% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Santersus Patents
Santersus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025048683-A1 | Method for detection and quantification of cell free dna in biological sample | Inactive | 25-Aug-2023 | ||
| US-12053567-B2 | Method and device for removal of circulating cell free dna | Active | 27-Dec-2021 | ||
| US-20230201439-A1 | Method and device for removal of circulating cell free dna | Active | 27-Dec-2021 | ||
| WO-2023126672-A1 | Method and device for removal of circulating cell free dna | Inactive | 27-Dec-2021 | ||
| WO-2022214873-A1 | The method and device for purification of blood from circulating citrullinated histones and neutrophil extracellular traps (nets) | Inactive | 05-Apr-2021 | A61M1/3679 |
Santersus Signals
Santersus Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Norcliffe Capital | Venture Capital | Minority | ||
| Terumo Ventures | Corporate Venture Capital | Minority |
Santersus Acquisitions (1)
Santersus’s most recent deal was a Merger/Acquisition with Xenetic Biosciences. The deal was made on 16-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xenetic Biosciences | 16-Sep-2026 | Merger/Acquisition | Drug Discovery |
Santersus FAQs
-
When was Santersus founded?
Santersus was founded in 2017.
-
Where is Santersus headquartered?
Santersus is headquartered in Zürich, Switzerland.
-
What is the size of Santersus?
Santersus has 7 total employees.
-
What industry is Santersus in?
Santersus’s primary industry is Therapeutic Devices.
-
Is Santersus a private or public company?
Santersus is a Private company.
-
What is Santersus’s current revenue?
The current revenue for Santersus is .
-
How much funding has Santersus raised over time?
Santersus has raised $8.35M.
-
Who are Santersus’s investors?
Norcliffe Capital and Terumo Ventures have invested in Santersus.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process